Göril Karlsson

557 total citations
10 papers, 460 citations indexed

About

Göril Karlsson is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Cellular and Molecular Neuroscience. According to data from OpenAlex, Göril Karlsson has authored 10 papers receiving a total of 460 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 5 papers in Pathology and Forensic Medicine and 4 papers in Cellular and Molecular Neuroscience. Recurrent topics in Göril Karlsson's work include Multiple Sclerosis Research Studies (4 papers), Neuroscience and Neuropharmacology Research (3 papers) and Sphingolipid Metabolism and Signaling (3 papers). Göril Karlsson is often cited by papers focused on Multiple Sclerosis Research Studies (4 papers), Neuroscience and Neuropharmacology Research (3 papers) and Sphingolipid Metabolism and Signaling (3 papers). Göril Karlsson collaborates with scholars based in Switzerland, United Kingdom and Germany. Göril Karlsson's co-authors include Hans-Rudolf Olpe, Mario F. Pozza, H. Bittiger, Martin W. Steinmann, Felix Brugger, Roger G. Hall, Henk van Riezen, Wolfgang Froestl, Graham E. Fagg and Ralf Gold and has published in prestigious journals such as Neurology, European Journal of Pharmacology and Neuroscience Letters.

In The Last Decade

Göril Karlsson

10 papers receiving 451 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Göril Karlsson Switzerland 8 306 225 98 75 58 10 460
Bertalan Csillik Hungary 12 213 0.7× 119 0.5× 34 0.3× 45 0.6× 108 1.9× 31 378
Douglas P. Dohrman United States 14 343 1.1× 348 1.5× 45 0.5× 39 0.5× 79 1.4× 20 697
Anna I. B. Adamo United States 9 232 0.8× 215 1.0× 52 0.5× 41 0.5× 30 0.5× 9 420
Leonardo Munari Italy 11 87 0.3× 148 0.7× 24 0.2× 78 1.0× 47 0.8× 23 445
Justin M. Farook United States 14 207 0.7× 224 1.0× 20 0.2× 38 0.5× 49 0.8× 17 420
Perrine Friedel France 6 260 0.8× 238 1.1× 17 0.2× 28 0.4× 46 0.8× 6 380
David A. Thorn United States 15 367 1.2× 263 1.2× 17 0.2× 57 0.8× 152 2.6× 21 547
Suzhen Gong United States 11 149 0.5× 114 0.5× 23 0.2× 55 0.7× 49 0.8× 14 381
Watkins Jc United States 8 394 1.3× 279 1.2× 36 0.4× 51 0.7× 64 1.1× 13 475
D. Blaine Moore United States 14 154 0.5× 142 0.6× 29 0.3× 23 0.3× 79 1.4× 22 607

Countries citing papers authored by Göril Karlsson

Since Specialization
Citations

This map shows the geographic impact of Göril Karlsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Göril Karlsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Göril Karlsson more than expected).

Fields of papers citing papers by Göril Karlsson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Göril Karlsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Göril Karlsson. The network helps show where Göril Karlsson may publish in the future.

Co-authorship network of co-authors of Göril Karlsson

This figure shows the co-authorship network connecting the top 25 collaborators of Göril Karlsson. A scholar is included among the top collaborators of Göril Karlsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Göril Karlsson. Göril Karlsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Bigaud, Marc, et al.. (2023). Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?. Neurology and Therapy. 12(4). 1187–1203. 1 indexed citations
2.
Gold, Ralf, Ludwig Kappos, Amit Bar‐Or, et al.. (2022). Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of Neurology. 269(9). 5093–5104. 12 indexed citations
3.
4.
Benedict, Ralph H. B., Davorka Tomic, Bruce Cree, et al.. (2021). Siponimod and Cognition in Secondary Progressive Multiple Sclerosis. Neurology. 96(3). e376–e386. 60 indexed citations
5.
Cree, Bruce, Baldur Magnusson, Nicolas Rouyrre, et al.. (2020). Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis. Multiple Sclerosis Journal. 27(10). 1564–1576. 15 indexed citations
6.
Benedict, Ralph H. B., Bruce Cree, Davorka Tomic, et al.. (2018). Impact of Siponimod on Cognition in Patients With Secondary Progressive Multiple Sclerosis: Results From Phase 3 EXPAND Study (S44.004). Neurology. 90(15_supplement). 6 indexed citations
7.
Olpe, Hans-Rudolf, Göril Karlsson, Mario F. Pozza, et al.. (1990). CGP 35348: a centrally active blocker of GABAB receptors. European Journal of Pharmacology. 187(1). 27–38. 272 indexed citations
8.
Karlsson, Göril & Hans-Rudolf Olpe. (1989). Inhibitory processes in normal and epileptic-like rat hippocampal slices: the role of GABAB receptors. European Journal of Pharmacology. 163(2-3). 285–290. 24 indexed citations
9.
Karlsson, Göril, Anne-Lise Jaton, & J. M. Vigouret. (1988). Dopamine D1- and D2-receptor interaction in turning behaviour induced by dopamine agonists in 6-hydroxydopamine-lesioned rats. Neuroscience Letters. 88(1). 69–74. 13 indexed citations
10.
Karlsson, Göril, Mario F. Pozza, & Hans-Rudolf Olpe. (1988). Phaclofen: a GABAB blocker reduces long-duration inhibition in the neocortex. European Journal of Pharmacology. 148(3). 485–486. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bertalan Csillik Breakdown of academic impact, for papers by Douglas P. Dohrman Breakdown of academic impact, for papers by Anna I. B. Adamo Breakdown of academic impact, for papers by Leonardo Munari Breakdown of academic impact, for papers by Justin M. Farook Breakdown of academic impact, for papers by Perrine Friedel Breakdown of academic impact, for papers by David A. Thorn Breakdown of academic impact, for papers by Suzhen Gong Breakdown of academic impact, for papers by Watkins Jc Breakdown of academic impact, for papers by D. Blaine Moore
Rankless by CCL
2026